• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Altimmune Inc.

    5/15/25 11:05:50 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Altimmune, Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    02155H200

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    02155H200


    1Names of Reporting Persons

    Ameriprise Financial, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    1,428,430.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    1,443,932.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,443,932.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.9 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    02155H200


    1Names of Reporting Persons

    TAM UK International Holdings Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    1,324,639.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    1,324,639.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,324,639.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.7 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP No.
    02155H200


    1Names of Reporting Persons

    Threadneedle Holdings Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    1,324,639.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    1,324,639.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,324,639.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.7 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP No.
    02155H200


    1Names of Reporting Persons

    TAM UK Holdings Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    1,324,639.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    1,324,639.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,324,639.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.7 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP No.
    02155H200


    1Names of Reporting Persons

    Threadneedle Asset Management Holdings Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    1,324,639.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    1,324,639.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,324,639.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.7 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP No.
    02155H200


    1Names of Reporting Persons

    TC Financing Ltd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    1,324,639.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    1,324,639.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,324,639.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.7 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP No.
    02155H200


    1Names of Reporting Persons

    Threadneedle Asset Management Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    1,324,639.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    1,324,639.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,324,639.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.7 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP No.
    02155H200


    1Names of Reporting Persons

    Threadneedle Investment Services Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    1,324,639.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    1,324,639.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,324,639.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.7 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Altimmune, Inc
    (b)Address of issuer's principal executive offices:

    910 Clopper Road, Suite 201S, Gaithersburg, Maryland 20878
    Item 2. 
    (a)Name of person filing:

    (a) Ameriprise Financial, Inc. ("AFI") (b) TAM UK International Holdings Limited ("TAMUKI") (c) Threadneedle Holdings Limited ("THL") (d) TAM UK Holdings Limited ("TUHL") (e) Threadneedle Asset Management Holdings Limited ("TAMHL") (f) TC Financing Ltd ("TCFL") (g) Threadneedle Asset Management Limited ("TAML") (h) Threadneedle Investment Services Limited ("TISL") Persons (a) through (h) are sometimes referred to herein as the "Ameriprise Entities".
    (b)Address or principal business office or, if none, residence:

    (a) 145 Ameriprise Financial Center, Minneapolis, MN 55474 (b) Cannon Place, 78 Cannon Street, London, EC4N 6AG (c) Cannon Place, 78 Cannon Street, London, EC4N 6AG (d) Cannon Place, 78 Cannon Street, London, EC4N 6AG (e) Cannon Place, 78 Cannon Street, London, EC4N 6AG (f) Cannon Place, 78 Cannon Street, London, EC4N 6AG (g) Cannon Place, 78 Cannon Street, London, EC4N 6AG (h) Cannon Place, 78 Cannon Street, London, EC4N 6AG
    (c)Citizenship:

    (a) Delaware (b) United Kingdom (c) United Kingdom (d) United Kingdom (e) United Kingdom (f) United Kingdom (g) United Kingdom (h) United Kingdom
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    02155H200
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Incorporated by reference to Items (5)-(9) and (11) of the cover page pertaining to each reporting person. AFI, as the parent company of the other Ameriprise Entities, may be deemed to beneficially own the shares reported herein by those reporting persons. Accordingly, the shares reported herein by AFI include those shares separately reported herein by those reporting persons. Each of the Ameriprise Entities disclaims beneficial ownership of any shares reported on this Schedule.
    (b)Percent of class:

    The information required by Item 4(b) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    AFI: See Exhibit I
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Ameriprise Financial, Inc.
     
    Signature:/s/ Michael G. Clarke
    Name/Title:Michael G. Clarke, Senior Vice President, North America Head of Operations & Investor Services
    Date:05/15/2025
     
    TAM UK International Holdings Limited
     
    Signature:/s/ Michael G. Clarke
    Name/Title:By: Columbia Management Investment Advisers, LLC, as Attorney in Fact, By: Michael G. Clarke, SVP, North America H.O. & Investor Services
    Date:05/15/2025
     
    Threadneedle Holdings Limited
     
    Signature:/s/ Michael G. Clarke
    Name/Title:By: Columbia Management Investment Advisers, LLC, as Attorney in Fact, By: Michael G. Clarke, SVP, North America H.O. & Investor Services
    Date:05/15/2025
     
    TAM UK Holdings Limited
     
    Signature:/s/ Michael G. Clarke
    Name/Title:By: Columbia Management Investment Advisers, LLC, as Attorney in Fact, By: Michael G. Clarke, SVP, North America H.O. & Investor Services
    Date:05/15/2025
     
    Threadneedle Asset Management Holdings Limited
     
    Signature:/s/ Michael G. Clarke
    Name/Title:By: Columbia Management Investment Advisers, LLC, as Attorney in Fact, By: Michael G. Clarke, SVP, North America H.O. & Investor Services
    Date:05/15/2025
     
    TC Financing Ltd
     
    Signature:/s/ Michael G. Clarke
    Name/Title:By: Columbia Management Investment Advisers, LLC, as Attorney in Fact, By: Michael G. Clarke, SVP, North America H.O. & Investor Services
    Date:05/15/2025
     
    Threadneedle Asset Management Limited
     
    Signature:/s/ Michael G. Clarke
    Name/Title:By: Columbia Management Investment Advisers, LLC, as Attorney in Fact, By: Michael G. Clarke, SVP, North America H.O. & Investor Services
    Date:05/15/2025
     
    Threadneedle Investment Services Limited
     
    Signature:/s/ Michael G. Clarke
    Name/Title:By: Columbia Management Investment Advisers, LLC, as Attorney in Fact, By: Michael G. Clarke, SVP, North America H.O. & Investor Services
    Date:05/15/2025

    Comments accompanying signature:   Contact Information Charles Chiesa VP Fund Treasurer Global Operations and Investor Services Telephone: 617-385-9593 Exhibit Index Exhibit I Identification and Classification of the Subsidiaries which Acquired the Security Being Reported on by the Parent Holding Company. Exhibit II Joint Filing Agreement Exhibit III Powers of Attorney
    Get the next $ALT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALT

    DatePrice TargetRatingAnalyst
    2/28/2025Mkt Perform
    William Blair
    1/8/2025$18.00Buy
    Stifel
    11/12/2024$26.00Buy
    UBS
    4/29/2024Buy → Neutral
    Guggenheim
    1/24/2024$13.00Neutral
    Goldman
    3/22/2023$20.00 → $6.00Buy → Neutral
    Goldman
    12/1/2022$20.00Buy
    Goldman
    12/29/2021$30.00Buy
    Jefferies
    More analyst ratings

    $ALT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Altimmune to Participate at Two Upcoming Investor Conferences

      GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences: H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, NY)Tuesday, May 20, 2025Fireside Chat at 10:00 a.m. Eastern Time Jefferies Global Healthcare Conference (New York, NY)Wednesday, June 4, 2025Fireside Chat at 9:55 a.m. Eastern Time The sessions will be webcast and can be accessed by visiting the Events section

      5/14/25 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

      GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in debt financing for life science companies, for up to $100 million in a credit facility, with a $15 million tranche funded at closing. Additional tranches will become available upon achievement of certain clinical and financial milestones aligned with the Company's pemvidutide development plans and financing needs. Access to this additional capital strengthens Altimmune's ba

      5/13/25 7:00:00 AM ET
      $ALT
      $HTGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Investment Managers
      Finance
    • Altimmune Announces First Quarter 2025 Financial Results and Business Update

      Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD), expected to initiate in Q2 and Q3 2025, respectively Cash, cash equivalents and short-term investments of $150 million as of March 31, 2025 $100 million credit facility secured with Hercules Capital, adding balance sheet strength and financial flexibility to support continued development of pemvidutide Webcast to be held today, May 13, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceuti

      5/13/25 7:00:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sohn Catherine A. bought $5,784 worth of shares (1,000 units at $5.78) (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/18/25 4:15:22 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Weaver Gregory L bought $51,996 worth of shares (10,000 units at $5.20) (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/14/25 7:27:34 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Altimmune

      William Blair initiated coverage of Altimmune with a rating of Mkt Perform

      2/28/25 7:17:56 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Altimmune with a new price target

      Stifel initiated coverage of Altimmune with a rating of Buy and set a new price target of $18.00

      1/8/25 7:32:53 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Altimmune with a new price target

      UBS initiated coverage of Altimmune with a rating of Buy and set a new price target of $26.00

      11/12/24 7:30:53 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    Financials

    Live finance-specific insights

    See more
    • Altimmune Announces First Quarter 2025 Financial Results and Business Update

      Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD), expected to initiate in Q2 and Q3 2025, respectively Cash, cash equivalents and short-term investments of $150 million as of March 31, 2025 $100 million credit facility secured with Hercules Capital, adding balance sheet strength and financial flexibility to support continued development of pemvidutide Webcast to be held today, May 13, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceuti

      5/13/25 7:00:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

      GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 13, 2025. Altimmune management will host a conference call at 8:30 am E.T. on May 13 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations

      5/6/25 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

      Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025 Company to hold virtual R&D Day on March 13, 2025. Program will include KOL presentations on pemvidutide development in obesity, MASH and additional indications Two pharmaceutical industry veterans added to Company Board of Directors Cash, cash equivalents and short-term investments of $131.9 million on December 31, 2024 Webcast to be held today, February 27, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Feb.

      2/27/25 7:00:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Altimmune Inc.

      SCHEDULE 13G/A - Altimmune, Inc. (0001326190) (Subject)

      5/15/25 11:05:50 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Altimmune Inc.

      10-Q - Altimmune, Inc. (0001326190) (Filer)

      5/13/25 4:55:02 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Altimmune, Inc. (0001326190) (Filer)

      5/13/25 7:04:35 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    Leadership Updates

    Live Leadership Updates

    See more
    • Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

      Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career Mr. Durso led biopharmaceutical company focused on liver disease as former CEO of Intercept Pharmaceuticals, previously oversaw multiple blockbuster franchises including cardiovascular and diabetes during 22-year tenure at Sanofi GAITHERSBURG, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) --  Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the expansion of its Board of Directors with the appointments of Teri Lawver and Jerry Durso. "We are thrilled

      2/25/25 7:30:00 AM ET
      $ALT
      $DXCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors

      GAITHERSBURG, Md., March 27, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of Directors. "We are delighted to welcome Catherine to our Board of Directors," said Vipin K. Garg, Ph.D., President and Chief Executive Officer. "Her broad experience in the pharmaceutical industry including strategic product development, business development and commercialization will be invaluable to Altimmune as we pursue our mission to develop next generation peptide therapeutics for obesity and liver disease." Dr. Sohn added, "I am very honored and pleased to join the Altimmun

      3/27/23 4:05:00 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Appoints Raymond Jordt as Chief Business Officer

      GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Raymond Jordt as Chief Business Officer, effective January 1, 2023. Mr. Jordt succeeds José Ochoa, who is leaving Altimmune to pursue other opportunities. Mr. Jordt is an accomplished executive with over 25 years of experience in the pharmaceutical industry. He joins Altimmune from Eli Lilly and Company, where he spent nearly two decades in various corporate and business development roles, most recently as Head of Transactions. During his tenure at Lilly, he led acquisitions, in/out-licensing, divestitures, collaborations, option

      1/4/23 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sohn Catherine A. bought $5,784 worth of shares (1,000 units at $5.78) (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/18/25 4:15:22 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Weaver Gregory L bought $51,996 worth of shares (10,000 units at $5.20) (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/14/25 7:27:34 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Harris Matthew Scott gifted 67,787 shares (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/11/25 4:05:11 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      11/14/24 11:58:56 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      10/17/24 11:16:51 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      10/16/24 4:21:16 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care